Fin Medium

Ipca is among India's top 20 pharmaceutical companies and is in the business of producing & marketing of  (a)  Active pharmaceutical ingredients (API) (b) Drug Intermediates (c) Formulations The company produces more than 150 formulations that include oral liquids, tablets, dry powders, and capsules and  its business in India focuses mainly on therapeutic segments like  Cardiovascular, Anti-diabetic, Pain management, Anti-malarial, Anti-bacterial, Anthelmintics, Central nervous system product, Gastrointestinal products, Cough preparations etc.  What is the difference between terms like API, Bulk drugs, Intermediates, Finished Dosage, and Formulations that are common jargons in the Pharmaceutical Industry? API  – Active Pharmaceutical Ingredient – is the basic drug itself with the desired medicinal (pharmaceutical) properties. Also referred to as Bulk Drugs. Intermediates  – Most chemical reactions are stepwise, that is they take more than one elementary step to complete. An API

Cadila Healthcare is one of the leading, innovation driven pharmaceutical companies in India and is in the business of -  Research & Development of New Chemical Entities (NCE) Manufacturing, marketing and selling of finished dosage human formulations Generics /  Branded Generics Specialty Formulations Biosimilars Vaccines Active pharmaceutical ingredients (APIs)  Animal healthcare products Consumer wellness products via its subsidiary  Zydus Wellness Limited New Chemical Entities (NCE) New Chemical Entity (NCE) research is characterized by large expenditures, long timelines especially in the late phases of clinical trials, increasingly stringent regulatory environment and the commercialization related uncertainties. The company is working on cutting edge technologies in different scientific disciplines to discover novel therapeutic agents. It has the capabilities to conduct drug discovery and development from concept to Investigational New Drug (IND) enabling pre-clinical and clini